نمایش پرونده ساده آیتم

dc.contributor.authorEivazi-Ziaei, J
dc.date.accessioned2018-08-26T06:32:56Z
dc.date.available2018-08-26T06:32:56Z
dc.date.issued2009
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/43504
dc.description.abstractAcute myeloid leukemia (AML) should be classified into subtypes according to the French-American-British (FAB) or, preferably, the newer World Health Organization (WHO) classification schemes. FAB is purely a morphological classification. It does not determine treatment (except M3) or prognosis for the patient which requires cytogenetics. Haematological analyzer had been used for classification of leukaemia in several studies. Neutrophil myeloperoxidase activity (MPXI) can be performed by Technicon H1 (Bayer) automated cell counter. The aim of this study was the statement of myeloperoxidase index and subgroups of AML. In the study of medical records of 72 patients with AML from 2006-7, we found that MPXI was negative in M4 and M5 while 75% of M3 cases had high MPXI values. MPXI level may help to differentiate subtypes of AML.
dc.language.isoEnglish
dc.relation.ispartofJPMA. The Journal of the Pakistan Medical Association
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectCase-Control Studies
dc.subjectFemale
dc.subjectHealth Status Indicators
dc.subjectHumans
dc.subjectLeukemia, Myeloid, Acute
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPeroxidase
dc.subjectPrognosis
dc.subjectYoung Adult
dc.titleMyeloperoxidase index and subtypes of acute myeloid leukemia.
dc.typearticle
dc.citation.volume59
dc.citation.issue6
dc.citation.spage406
dc.citation.epage7
dc.citation.indexPubmed


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم